CA3087019A1 — Pharmaceutical preparation containing pyridyl aminoacetic acid compound
Assigned to Santen Pharmaceutical Co Ltd · Expires 2019-07-04 · 7y expired
What this patent protects
The purpose of the present invention is to discover a pharmaceutical preparation which is for treating or preventing glaucoma or intraocular hypertension and exhibits effects on a patient in which the efficacy of a therapeutic agent for glaucoma or intraocular hypertension is ins…
USPTO Abstract
The purpose of the present invention is to discover a pharmaceutical preparation which is for treating or preventing glaucoma or intraocular hypertension and exhibits effects on a patient in which the efficacy of a therapeutic agent for glaucoma or intraocular hypertension is insufficient. It is found that omidenepag, an ester thereof, or a salt thereof is proven to exhibit an excellent intraocular tension depressive action on a patient in which the efficacies of other therapeutic agents for glaucoma or intraocular hypertension are insufficient. Therefore, omidenepag, an ester thereof, or a salt thereof according to the present invention is useful as a pharmaceutical preparation capable of treating or preventing glaucoma or intraocular hypertension even on a patient in which the efficacies of other therapeutic agents for glaucoma or intraocular hypertension are insufficient.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.